Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Isaias, Ioannis U ^a,b,c   Marotta, Giorgio ^d   Pezzoli, Gianni ^b   Sabri, Osama ^c   Schwarz, Johannes ^c   Crenna, Paolo ^a   Classen, Joseph ^c   Cavallari, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA(4 IODOPHENYL)TROPANE I 123; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; ROPINIROLE; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CONTROLLED STUDY; FEMALE; HUMAN; LOCUS CERULEUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROIMAGING; PARKINSON DISEASE; PUTAMEN; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; HISTORY; METABOLISM; SCINTISCANNING;

ADULT; AGED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HISTORY, 17TH CENTURY; HUMANS; LOCUS COERULEUS; MALE; PARKINSON DISEASE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 79960561387     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-88     Document Type: Article

References (40)

1. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991, 88:47-75.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211. 10.1016/S0197-4580(02)00065-9, 12498954.
3. Collingridge GL, James TA, MacLeod NK. Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra. 1979, 290:44.
4. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease?. Neurology 1980, 30:1326-1330.
5. Guiard BP, El Mansari M, Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 2008, 74:1463-1475. 10.1124/mol.108.048033, 18703671.
6. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322. 10.1093/brain/awh445, 15716302.
7. Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC. The locus ceruleus and dementia in Parkinson's disease. Neurology 1993, 43:986-991.
8. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi J. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788. 10.1093/brain/awm056, 17412731.
9. Ørskov L, Jakobsen J, Dupont E, de Fine Olivarius B, Christensen NJ. Autonomic function in Parkinsonian patients relates to duration of disease. Neurology 1987, 37:1173-1178.
10. Devoto P, Flore G. On the origin of cortical dopamine. Is it a co-transmitter in noradrenergic neurons?. Curr Neuropharmacol 2006, 4:115-125. 10.2174/157015906776359559, 2430672, 18615131.
11. Cornil CA, Ball GF. Interplay among Catecholamine Systems: Dopamine Binds to α2-Adrenergic Receptors in Birds and Mammals. J comp neurol 2008, 511:610-627. 10.1002/cne.21861, 2858410, 18924139.
12. Waterhouse BD, Devilbiss D, Fleischer D, Sessler FM, Simpson KL. New perspectives on the functional organization and postsynaptic influences of the locus ceruleus efferent projection system. Adv Pharmacol 1998, 42:749-754.
13. Logan J, Wang G, Telang F, Fowler JS, Alexoff D, Zabroski J. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nuc Med Biol 2007, 34:667-679.
14. Booij J, Kemp P. Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008, 35:424-438. 10.1007/s00259-007-0621-0, 17968545.
15. Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, Pezzoli G, Antonini A. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. Neuroreport 2007, 14:1499-1502.
16. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 2002, 45:125-133. 10.1002/syn.10090, 12112405.
17. Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA. In vivo mapping of the human locus coeruleus. NeuroImage 2009, 47:1261-1267. 10.1016/j.neuroimage.2009.06.012, 19524044.
18. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nuc Med Mol Imaging 2007, 34:1240-1253.
19. Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW. Inhibitory effect of reserpine on dopamine transporter function. Eur J Pharmacol 2002, 456:39-43. 10.1016/S0014-2999(02)02647-X, 12450567.
20. Zahniser NR, Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Semin Cell Dev Biol 2009, 20:411-417. 10.1016/j.semcdb.2009.01.004, 19560046.
21. Ordway GA, Stockmeier CA, Cason GW, Klimek V. Pharmacology and Distribution of Norepinephrine Transporters in the Human Locus Coeruleus and Raphe Nuclei. Journal Neurosci 1997, 17:1710-1719.
22. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000, 47:493-503. 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4, 10762161.
23. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998, 44(Suppl 1):10-18.
24. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson's disease: An 18F-dopa PET study. Neurobiol of Dis 2008, 29:381-390.
25. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006, 17:1215-1218. 10.1097/01.wnr.0000227984.84927.a7, 16837857.
26. Chernoloz O, Mansari ME, Blier P. Sustained administration of pramipexole modifies the spontaneous firing rate of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009, 34:651-661. 10.1038/npp.2008.114, 18688211.
27. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 2000, 97:6850-6855. 10.1073/pnas.110035297, 18764, 10823899.
28. Kahlig KM, Javitch JA, Galli A. Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging suport the endocytosis of an active carrier. J Biol Chem 2004, 279:8966-8975. 10.1074/jbc.M303976200, 14699142.
29. Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009, 256(Suppl 3):270-279.
30. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H. α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005, 128:2654-2664. 10.1093/brain/awh584, 16000336.
31. Hoogendijk WJ, Pool CW, Troost D, van Zwieten E, Swaab DF. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995, 118:131-43. 10.1093/brain/118.1.131, 7894999.
32. McMillan PJ, White SS, Franklin A, Greenupa JL, Leverenz JB, Raskind MA, Szot P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 2011, 1373:240-252.
33. Cornil CA, Balthazart J, Motte P, Massotte L, Seutin V. Dopamine activates noradrenergic receptors in the preoptic area. J Neurosci 2002, 22:9320-9330.
34. Newman-Tancredi A, Audinot-Bouchez V, Gobert A, Millan MJ. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur J Pharmacol 1997, 319:379-383. 10.1016/S0014-2999(96)00985-5, 9042615.
35. Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 2002, 41:357-365. 10.1016/S0197-0186(02)00049-9, 12176079.
36. Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F, Michel PP. The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol Pharmacol 2005, 67:1882-91. 10.1124/mol.104.007864, 15784847.
37. Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behavioral-sensitizing doses of methamphetamine. Eur J Pharmacol 1997, 334:273-279. 10.1016/S0014-2999(97)01152-7, 9369358.
38. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus on parkinsonian signs, striatal dopamine and substantia nigra cel loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys: a possible role for the locus coeruleus in progression of Parkinson's disease. Neuroscience 1991, 41:507-523. 10.1016/0306-4522(91)90345-O, 1870701.
39. Rommelfanger KS, Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson disease. Biochem Pharmacol 2007, 74:177-190. 10.1016/j.bcp.2007.01.036, 17416354.
40. Berglöf E, Strömberg I. Locus coeruleus promotes survival of dopamine neurons in ventral mesencephalon. An in oculo grafting study. Exp Neurol 2009, 216:158-65. 10.1016/j.expneurol.2008.11.029, 19150447.